By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Shionogi, Inc. 

100 Campus Drive

Florham Park  New Jersey  07932  U.S.A.
Phone: 973-966-6900 Fax: n/a



Company News
Shionogi Presents New Clinical And Non-Clinical Data On S-033188, An Investigational Cap-Dependent Endonuclease Inhibitor For Treatment Of Influenza, At The 27th European Congress Of Clinical Microbiology And Infectious Diseases 4/24/2017 7:47:31 AM
Shionogi, Inc. Release: Naldemedine Phase 3 Study Shows Significant Improvement For Patients With Opioid-Induced Constipation 2/19/2016 7:33:57 AM
Shionogi, Inc. Initiates Phase 3 Clinical Study Of Osphena For The Treatment Of Postmenopausal Vaginal Dryness 12/2/2015 6:11:26 AM
New Shionogi, Inc. Advertising Campaign Features A Personal Story About Painful Sex After Menopause 9/9/2015 9:45:35 AM
Shionogi, Inc.'s Naldemedine Meets Endpoints In Phase III Study 8/3/2015 7:04:58 AM
Shionogi, Inc. Release: Phase IIb Data Show Once-Daily Naldemedine Provides Significant Improvement For Patients With Opioid-Induced Constipation 5/19/2015 7:53:34 AM
Egalet Earns $10 Million Milestone Payment Triggered By Advancement Of Shionogi, Inc.'s Abuse-Deterrent, Extended-Release Hydrocodone, S-718632, Using Egalet's GuardianTechnology 3/17/2015 7:06:26 AM
Shionogi, Inc. Release: Novel Siderophore Cephalosporin S-649266 Pre-Clinical Results Suggest Potent Activity Against Multidrug-Resistant Gram-Negative Pathogens 10/9/2014 12:31:38 PM
Shionogi, Inc. Announces Four Abstracts To Be Presented At The 25th Annual Meeting Of The North American Menopause Society (NAMS) In Washington, DC 10/1/2014 9:35:16 AM
Shionogi, Inc. Pledges To "Take Charge" In Honor Of Menopause Awareness Month 9/8/2014 9:16:20 AM